Ranking Profile - BridgeBio Pharma Inc

Introduction

BridgeBio Pharma Inc (BridgeBio) is a clinical-stage biotechnology company that develops novel medicines for genetic diseases. The company’s pipeline product portfolio includes precision cardiorenal drugs such as acoramidis, encaleret, BBP-711; mendelian disease drugs which include acoramidis, fosdenopterin, patidegib topical gel, low-dose infigratnib, BBP-589, BBP-551, BBP-418, BBP-681, BBP-671, among others; precision oncology drugs which include high-dose infigratinib, BBP-398, BBP-454, BBP-954. BridgeBio also carries out various phases of clinical trials such as pre-clinical, phase I, phase II studies. The company’s academic partners which include Medical University of South Carolina, University of Pittsburgh, Oregon Health, and Science University, among others. Its industry partners which include Helsinn, Alexion, Bristol Myers Squibb, among others. BridgeBio is headquartered in Palo Alto, California, the US.